Endocrinology Stocks
Precision biochemical innovators in this space develop therapies and delivery systems targeting hormonal imbalances, metabolic disorders, and rare endocrine pathologies. Revenue models center on high-barrier intellectual property, ranging from proprietary insulin delivery platforms and GLP-1 agonists to orphan drugs for congenital adrenal hyperplasia.
As of Oct 23, 2026, Endocrinology has 22 US-listed companies worth $182B combined. The median member moved +3.4% over the past week; BBNX led at +17.2% and BMEA trailed at -30.9%.
Companies in Endocrinology
- SNY – Sanofi ADR, $99.7B
- ASND – Ascendis Pharma AS, $16B
- NBIX – Neurocrine Biosciences Inc, $14.6B
- CORT – Corcept Therapeutics Incorporated, $11.6B
- PODD – Insulet Corporation, $10.3B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- MMED – MiniMed Group, Inc. Common Stock, $5.2B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- VKTX – Viking Therapeutics Inc, $3.3B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- XERS – Xeris Pharmaceuticals Inc, $2B
- SEPN – Septerna, Inc. Common Stock, $1.8B
- ETON – Eton Pharmaceuticals Inc, $1.6B
- MNKD – MannKind Corp, $1.2B
- BBNX – Beta Bionics, Inc. Common Stock, $1B
- OLMA – Olema Pharmaceuticals Inc, $684M
- ENTX – Entera Bio Ltd, $435M
- EMBC – Embecta Corp, $389M
- SPRB – Spruce Biosciences, Inc. Common Stock, $116M
- BMEA – Biomea Fusion Inc, $50M
- LPCN – Lipocine Inc, $16.9M
- MODD – Modular Medical Inc, $15.9M